New Drug Approvals 2012 - Pt. III - Axitinib (INLYTA®)
Frontiers | The Paradoxical Role of Cellular Senescence in Cancer
New Drug Approvals 2012 - Pt. III - Axitinib (INLYTA®)
Axitinib - wikidoc
Product Name : Axitinib N-Glucuronide | Pharmaffiliates
Renal cell carcinoma - Wikiwand
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ScienceDirect
Rifampicin 13292-46-1 wiki
INLYTA® (axitinib) - Cancer Therapy Advisor
Axitinib | C22H18N4OS | CID 6450551 - PubChem
Axitinib | C22H18N4OS | CID 6450551 - PubChem
Update on thyroid cancer treatment | Future Oncology
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ScienceDirect
File:VEGFR2 bound to axitinib.gif - Wikimedia Commons
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer
319460-85-0 Axitinib - Watson International Ltd
PharmaWiki - Axitinib
AXITINIB
Axitinib - wikidoc
Von Hippel–Lindau tumor suppressor - Wikipedia
Papillary renal cell carcinoma - Wikipedia
Axitinib - wikidoc
Axitinib-Impurities | Pharmaffiliates
Axitinib | C22H18N4OS | ChemSpider
INLYTA® (axitinib) - Cancer Therapy Advisor
